2026-05-21T23:08:51Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/185152024-11-28T14:51:11Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc Ciano-Petersen, Nicolás Lundahl author Cabezudo-García, Pablo author Muñiz-Castrillo, Sergio author Honnorat, Jérôme author Serrano-Castro, Pedro Jesús author Oliver-Martos, Begoña author 2021-12-04 The discovery of biomarkers in rare diseases is of paramount importance to allow a better diagnosis, improve predictions of outcomes, and prompt the development of new treatments. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a rare autoimmune disorder associated with the presence of antibodies targeting the GluN1 subunit of the NMDAR. Since it was discovered in 2007, large efforts have been made towards the identification of clinical, paraclinical, and molecular biomarkers to better understand the immune mechanisms that govern the course of the disease as well as to define predictors of treatment response and long-term outcomes. However, most of these biomarkers are still in an exploratory phase, with only a few candidates reaching the final phases of the always-complex process of biomarker development, mainly due to the low incidence of the disease and its recent description. Clinical and paraclinical markers are probably the most widely explored in anti-NMDAR encephalitis, five of them combined in a clinical score to predict 1 year outcome. On the contrary, soluble molecules, such as persistent antibody positivity, antibody titers, cytokines, and other inflammatory mediators, have been proposed as biomarkers of clinical activity, inflammation, prognosis, and treatment response, but further studies are required for their clinical validation including larger and more homogenous cohorts of patients. Similarly, genetic susceptibility biomarkers are still in the exploratory phase and, therefore, weak conclusions can for now only be achieved. Thus, further studies are warranted to define biomarkers and unravel the underlying mechanisms driving rare diseases such as anti-NMDAR encephalitis. Future international collaborative studies with prospective designs that enable the enrollment of large cohorts will allow for the identification and validation of novel biomarkers for clinical decision-making. 10.3390/ijms222313127 1422-0067 International Journal of Molecular Sciences http://hdl.handle.net/10668/3960 34884930 http://hdl.handle.net/20.500.12105/18515 Anti-NMDAR encephalitis Biomarker Rare diseases Autoimmune encephalitis Encefalitis por antirreceptores de N-metil-D-aspartato Biomarcadores Enfermedades raras Encefalitis Enfermedades autoinmunes Current Status of Biomarkers in Anti-N-Methyl-D-Aspartate Receptor Encephalitis